Polyphosphoester-based cationic nanoparticles serendipitously release integral biologically-active components to serve as novel degradable inducible nitric oxide synthase inhibitors.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23999874.
- Also identified by DOI 10.1002/adma.201302842 and PMC identifier 4404032.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A degradable polyphosphoester (PPE)-based cationic nanoparticle (cSCK), which is integrated constructed as a novel degradable drug device, demonstrates surprisingly efficient inhibition of inducible nitric oxide synthase (iNOS) transcription, and eventually inhibits nitric oxide (NO) over-production, without loading of any specific therapeutic drugs. This system may serve as a promising anti-inflammatory agent toward the treatment of acute lung injury.
Medical subject headings
- Enzyme Inhibitors
- Nanoparticles
- Nitric Oxide Synthase Type II
- Polymers